Two Northwestern Medicine studies are improving the understanding of epigenetic mechanisms in cancer development and progression, and identifying novel cancer driver genes that may help identify patients who will benefit from immunotherapy.
A team of Northwestern Medicine investigators led by Rina Fox, PhD, MPH, received a Cancer and Aging Translational Bridge Award to investigate circadian disruption in lymphoma.
An FDA-approved monoclonal antibody drug used to treat advanced bladder cancer demonstrated poor efficacy in a recent clinical trial.
Boosting mitochondrial function in a subpopulation of T cells could make cancer immunotherapy more effective, according to a recent study.
Northwestern Medicine scientists have discovered a mechanism that makes a prostate cancer-causing protein called FOXA1 more resilient, according to a recent study.
Northwestern Medicine investigators have discovered how a particular type of immune cell exerts a dual function in cancer cells that is contingent on tumor grade.
Inhibiting production of a key material produced by the mTOR pathway could slow tumor growth, according to a recent Northwestern Medicine study.
Inhibiting a novel protein variant within glioma stem cells may be a promising therapeutic approach to treat glioblastoma, according to a recent Northwestern Medicine study.
A novel integrative computational technique allowed scientists to classify disease conditions at the molecular level using epigenomic data sets.
Northwestern Medicine investigators have discovered that inhibiting tumor-associated myeloid cells ability to produce specialized metabolites called polyamines may improve the effectiveness of treatments for glioblastoma.